(Q37428676)

English

Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities

scientific article published on April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

author name string

Hugo F Fernandez

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Mohamed A Kharfan-Dabaja

2

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

publication date

1 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

153-157

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

How I treat chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy

1 reference

https://api.crossref.org/works/10.1177%2F107327480901600207

21 January 2018

Identifiers

10.1177/107327480901600207

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37428676&oldid=1705896253"